Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancer.

NPJ precision oncology·2026
Same author

Infestation by <i>Sarcoptes scabiei</i> causes distinct differences in sarcoptic mange disease syndromes among sympatric carnivoran species.

International journal for parasitology. Parasites and wildlife·2026
Same author

Nasal Air-Jet Sensitivity Differentiates Empty Nose Syndrome and Turbinate Reduction Patients: A Pilot Study.

The Laryngoscope·2026
Same author

Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancer.

medRxiv : the preprint server for health sciences·2026
Same author

Quantifying ocean monitoring effort and cost in the Southern California Bight over the last 25 years.

Journal of environmental management·2025
Same author

Metabolic and imaging phenotypes associated with RB1 and TP53 loss in prostate cancer.

Neoplasia (New York, N.Y.)·2025

Related Experiment Video

Updated: May 22, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

Prostate cancer stem cells: The case for model systems.

Paul G Hynes1, Kathleen Kelly

  • 1Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Journal of Carcinogenesis
|April 25, 2012
PubMed
Summary

Castration-resistant prostate cancer arises from tumor heterogeneity, potentially driven by cancer stem cells (CSCs). Understanding prostate CSCs is key to developing new therapies against advanced prostate cancer.

Keywords:
Animal modelscancer stem cellscastration resistanceprostate cancer

More Related Videos

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
09:04

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol

Published on: November 14, 2025

Formation of Human Prostate Epithelium Using Tissue Recombination of Rodent Urogenital Sinus Mesenchyme and Human Stem Cells
08:44

Formation of Human Prostate Epithelium Using Tissue Recombination of Rodent Urogenital Sinus Mesenchyme and Human Stem Cells

Published on: June 22, 2013

Related Experiment Videos

Last Updated: May 22, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
07:16

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples

Published on: March 14, 2014

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol
09:04

Establishment and Maintenance of Patient-derived Prostate Cancer Organoids: A Detailed Experimental Protocol

Published on: November 14, 2025

Formation of Human Prostate Epithelium Using Tissue Recombination of Rodent Urogenital Sinus Mesenchyme and Human Stem Cells
08:44

Formation of Human Prostate Epithelium Using Tissue Recombination of Rodent Urogenital Sinus Mesenchyme and Human Stem Cells

Published on: June 22, 2013

Area of Science:

  • Oncology
  • Cancer Biology
  • Urology

Background:

  • Advanced prostate cancer treatment relies on androgen deprivation therapy (ADT).
  • ADT often leads to treatment resistance and metastatic disease, driven by tumor heterogeneity.
  • Cancer stem cells (CSCs) are implicated in tumor heterogeneity and treatment resistance.

Purpose of the Study:

  • To review mechanisms of castration resistance in prostate cancer.
  • To explore the role of androgen-independent prostate CSCs in treatment resistance.
  • To discuss the utility of preclinical models for characterizing prostate CSCs.

Main Methods:

  • Literature review on castration resistance mechanisms.
  • Discussion of cancer stem cell (CSC) hypothesis in prostate cancer.
  • Analysis of preclinical models for CSC characterization.

Main Results:

  • Tumor heterogeneity and CSCs are central to castration-resistant prostate cancer.
  • Androgen-independent CSCs are hypothesized to drive resistance.
  • Preclinical models are crucial for studying CSCs under varying androgen conditions.

Conclusions:

  • Identifying and characterizing prostate CSCs is fundamental for understanding and treating advanced prostate cancer.
  • Targeted therapies aimed at CSCs may prevent castration-resistant disease.
  • Further research using preclinical models is needed to fully elucidate CSC roles.